● The company's losses deepened as it invested in commercialization.
●New patent:On August 5, 2026, Vivos announced U.S.PatentNo. 12,697,190, broadening protection for its Vivos CARE oral medical-device technology.
GeoVax Labs (NASDAQ:GOVX) is advancing an ambitious vaccine and immunotherapy pipeline against a backdrop of tight finances. The company is pushing forward with late-stage plans for a smallpox and mpox vaccine while flagging the funding challenges that shadow many small biotechs.
Kairos Pharma (NYSE:KAPA) is a small oncology company assembling a body of clinical evidence for a novel antibody, and a series of positive interim readouts has begun to build a case that the stock deserves a fresh look. The company's lead candidate targets a …
● The company described a rebound in revenue and maintained its guidance.
Nano-X Imaging (NASDAQ:NNOX) is pursuing an ambitious vision to make medical imaging more accessible through novel X-ray technology and AI, and recent commercial deals suggest the company is quietly building momentum. After years of development and skepticism, Nano-X has been signing multi-year deployment agreements …
●Delisting determination:On August 19, 2026, OSR Health disclosed it had received aNasdaqStaff Delisting Determination for failing to maintain the $1.00 minimum bid price.
Quince Therapeutics (NASDAQ:QNCX) has had one of the more difficult years a clinical-stage biotech can face: its pivotal trial failed, and the company moved to halt development of its lead program. Investors considering the shares should focus on what the company actually has left …
Aldeyra Therapeutics (NASDAQ:ALDX) has spent years navigating a winding regulatory path for its dry-eye-disease drug, and the story has reached another pivotal juncture. After earlier setbacks with the FDA, the company resubmitted its application for reproxalap, secured FDA acceptance for review, and expanded aPartnershipwith …
●Strong response data:Curis reported an 86% response rate in a BTK-inhibitor-naive lymphoma setting for emavusertib, its lead IRAK4 inhibitor.